Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Medications to Manage Gallbladder Disease on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Label instruction / Gallbladder studies if cholelithiasis or cholecystitis are suspected [1]
  • Label on a gallbladder medicine / None named for gallstones or cholecystitis [1]
  • Ozempic maintenance doses / 0.5, 1 or 2 mg once weekly [1]
  • SELECT, semaglutide 2.4 mg / Gallbladder-related disorders 2.8% vs 2.3% [2]
  • GLP-1 class meta-analysis / Gallbladder disorders 26% higher than control [3]
  • Semaglutide meta-analysis / Gallbladder disorders OR 1.26; cholelithiasis OR 2.06 [4]

What the Ozempic label says to do

Ozempic is approved for type 2 diabetes, and its maintenance doses are 0.5, 1 or 2 mg once weekly [1]. The label lists acute gallbladder disease under warnings and precautions, and its instruction for suspected stones or gallbladder inflammation is that gallbladder studies are indicated [1]. The Rybelsus and Ozempic tablets label carries the same warning [5].

That warning is about diagnosis, not about which drug to prescribe afterward.

How often do gallbladder problems occur on semaglutide?

SELECT followed 17,604 adults with established cardiovascular disease and overweight or obesity on semaglutide 2.4 mg or placebo. Gallbladder-related disorders occurred in 2.8% vs 2.3%, driven mainly by cholelithiasis at 1.4% vs 1.1%; cholecystitis was 0.6% in both groups [2][6].

Two pooled analyses put the class signal in context. Across 21 trials and 99,599 patients, GLP-1 receptor agonists were associated with 26% more gallbladder disorders than control [3]. In nine trials of semaglutide in adults with overweight or obesity without diabetes, gallbladder disorders had an odds ratio of 1.26 and cholelithiasis 2.06 [4]. Neither analysis tested a medicine to prevent or treat those events.

What medicines does the label recommend?

The Ozempic label names no medicine for gallstones or cholecystitis, and no medicine ranking can be drawn from the label or from the trials and analyses above. If either condition is suspected, the label says gallbladder studies are indicated [1].

Does the label say to stop Ozempic?

For stones or cholecystitis, the label pairs the gallbladder warning with gallbladder studies, not with a stop instruction [1]. The pancreatitis instruction is explicit: the label says to discontinue Ozempic if pancreatitis is suspected, and describes persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, as the picture to watch for [1].

Frequently asked questions

Does Ozempic cause gallstones?
The label lists acute gallbladder disease as a warning and says gallbladder studies are indicated if cholelithiasis or cholecystitis are suspected [1]. In SELECT, gallbladder-related disorders occurred in 2.8% of people taking semaglutide 2.4 mg and 2.3% taking placebo [2].
Are gallstones a contraindication to Ozempic?
The label does not list gallstones or cholecystitis as contraindications. It lists a personal or family history of medullary thyroid carcinoma or MEN 2, and a prior serious hypersensitivity reaction to semaglutide or an excipient [1].
Does the gallbladder warning apply to 0.5, 1 and 2 mg?
The warning is not written for one dose. Ozempic maintenance is 0.5, 1 or 2 mg once weekly, and the gallbladder warning sits in the same warnings section for the product [1].

References

  1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
  2. Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025;33(3):452-462. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
  3. Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86(20):1805-1819. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
  4. Kommu S, Berg RL. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25(9):e13792. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials
  5. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
  6. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Evidence overview for Medications to Manage Gallbladder Disease on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond